share_log

Intuitive Surgical | 10-Q: Q3 2024 Earnings Report

Intuitive Surgical | 10-Q: Q3 2024 Earnings Report

直觉外科公司 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/19 04:49

Moomoo AI 已提取核心信息

Intuitive Surgical reported robust Q3 2024 financial results, with total revenue increasing 17% to $2.04 billion. Instruments and accessories revenue grew 18% to $1.26 billion, driven by an 18% rise in da Vinci procedures to 670,000 and a 73% increase in Ion procedures to 25,000. Systems revenue rose 17% to $445 million as the company placed 379 da Vinci systems, including 110 next-generation da Vinci 5 systems.Operating income increased 24% to $577 million, with a gross profit margin of 67.4%. The company maintained strong profitability despite higher costs associated with the da Vinci 5 surgical system launch. The installed base grew 15% year-over-year to approximately 9,539 da Vinci systems globally, while the Ion system installed base expanded 50% to 736 systems.Geographic expansion continued with strong procedure growth in Japan, Germany, UK, India, France, and Italy. The company ended the quarter with $8.31 billion in cash and investments, up $0.97 billion from year-end 2023. Looking ahead, Intuitive expects continued investments in product development and manufacturing capacity expansion, with planned capital expenditures of $1-1.2 billion in 2024.
Intuitive Surgical reported robust Q3 2024 financial results, with total revenue increasing 17% to $2.04 billion. Instruments and accessories revenue grew 18% to $1.26 billion, driven by an 18% rise in da Vinci procedures to 670,000 and a 73% increase in Ion procedures to 25,000. Systems revenue rose 17% to $445 million as the company placed 379 da Vinci systems, including 110 next-generation da Vinci 5 systems.Operating income increased 24% to $577 million, with a gross profit margin of 67.4%. The company maintained strong profitability despite higher costs associated with the da Vinci 5 surgical system launch. The installed base grew 15% year-over-year to approximately 9,539 da Vinci systems globally, while the Ion system installed base expanded 50% to 736 systems.Geographic expansion continued with strong procedure growth in Japan, Germany, UK, India, France, and Italy. The company ended the quarter with $8.31 billion in cash and investments, up $0.97 billion from year-end 2023. Looking ahead, Intuitive expects continued investments in product development and manufacturing capacity expansion, with planned capital expenditures of $1-1.2 billion in 2024.
直觉外科公司报告了2024年第三季度强劲的财务业绩，总营业收入增长了17%，达到了20.4亿美金。仪器和配件的营业收入增长了18%，达到了12.6亿美金，这得益于达芬奇手术数量增长了18%，达到670,000次，而离子手术数量增长了73%，达到了25,000次。系统营业收入上涨了17%，达到44500万美金，公司交付了379台达芬奇系统，其中包括110台下一代达芬奇5系统。营业收入增长了24%，达到57700万美金，毛利润率为67.4%。尽管与达芬奇5外科系统的发布相关的成本增加，公司仍维持了强劲的盈利能力。全球已安装的达芬奇系统基数同比增长了15%，约为9,539台，而离子系统的已安装基数扩...展开全部
直觉外科公司报告了2024年第三季度强劲的财务业绩，总营业收入增长了17%，达到了20.4亿美金。仪器和配件的营业收入增长了18%，达到了12.6亿美金，这得益于达芬奇手术数量增长了18%，达到670,000次，而离子手术数量增长了73%，达到了25,000次。系统营业收入上涨了17%，达到44500万美金，公司交付了379台达芬奇系统，其中包括110台下一代达芬奇5系统。营业收入增长了24%，达到57700万美金，毛利润率为67.4%。尽管与达芬奇5外科系统的发布相关的成本增加，公司仍维持了强劲的盈利能力。全球已安装的达芬奇系统基数同比增长了15%，约为9,539台，而离子系统的已安装基数扩展了50%，达到了736台。地理扩张持续进行，在日本、德国、英国、印度、法国和意大利的手术数量增长显著。公司在季度末的现金和投资总额为83.1亿美金，比2023年年末增加了9.7亿美金。展望未来，直觉外科公司预计将继续投资于产品开发和制造能力的扩展，计划在2024年进行10-12亿美金的资本支出。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Femasys
    FEMY
    -- 1.5900
    Predictive Oncology
    POAI
    -- 1.6200
    West Pharmaceutical Services
    WST
    -- 214.730
    NexGel
    NXGL
    -- 3.530
    BioNano Genomics
    BNGO
    -- 5.7600
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！